INTEGRA LIFESCIENCES HOLDINGS CORP Cost of Revenue
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) reported Cost of Revenue of $199.02 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-07-29
- INTEGRA LIFESCIENCES HOLDINGS CORP cost of goods and services sold for the quarter ending 2026-06-30 was $199.02M, a 3.52% decline year-over-year.
- INTEGRA LIFESCIENCES HOLDINGS CORP cost of goods and services sold for the quarter ending 2026-03-31 was $174.94M, a 7.06% decline year-over-year.
- INTEGRA LIFESCIENCES HOLDINGS CORP cost of goods and services sold for the quarter ending 2025-12-31 was $214.06M, a 10.58% increase year-over-year.
- INTEGRA LIFESCIENCES HOLDINGS CORP cost of goods and services sold for the quarter ending 2025-09-30 was $195.07M, a 8.02% increase year-over-year.
- INTEGRA LIFESCIENCES HOLDINGS CORP cost of goods and services sold for fiscal 2025 was $803.63M, a 10.32% increase from fiscal 2024.
- INTEGRA LIFESCIENCES HOLDINGS CORP cost of goods and services sold for fiscal 2024 was $728.47M, a 10.90% increase from fiscal 2023.
- INTEGRA LIFESCIENCES HOLDINGS CORP cost of goods and services sold for fiscal 2023 was $656.84M, a 11.83% increase from fiscal 2022.
- INTEGRA LIFESCIENCES HOLDINGS CORP cost of goods and services sold for fiscal 2022 was $587.36M, a 1.75% decline from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $199.02M 10-Q · filed 2026-07-29 | $373.95M 10-Q · filed 2026-07-29 | $588.01M derived: sum of 3 quarters · filed 2026-07-29 | $783.08M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $174.94M 10-Q · filed 2026-05-05 | $389.00M derived: sum of 2 quarters · filed 2026-05-05 | $584.07M derived: sum of 3 quarters · filed 2026-05-05 | $790.34M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $214.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $409.13M derived: sum of 2 quarters · filed 2026-02-26 | $615.40M derived: sum of 3 quarters · filed 2026-07-29 | $803.63M 10-K · filed 2026-02-26 |
| 2025-09-30 | $195.07M 10-Q · filed 2025-10-30 | $401.34M derived: sum of 2 quarters · filed 2026-07-29 | $589.57M 10-Q · filed 2025-10-30 | $783.14M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $206.27M 10-Q · filed 2026-07-29 | $394.49M 10-Q · filed 2026-07-29 | $588.07M derived: sum of 3 quarters · filed 2026-07-29 | $768.66M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $188.22M 10-Q · filed 2026-05-05 | $381.80M derived: sum of 2 quarters · filed 2026-05-05 | $562.39M derived: sum of 3 quarters · filed 2026-05-05 | $754.65M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $193.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $374.17M derived: sum of 2 quarters · filed 2026-02-26 | $566.43M derived: sum of 3 quarters · filed 2026-02-26 | $728.47M 10-K · filed 2026-02-26 |
| 2024-09-30 | $180.60M 10-Q · filed 2025-10-30 | $372.85M derived: sum of 2 quarters · filed 2025-10-30 | $534.89M 10-Q · filed 2025-10-30 | $705.44M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $192.26M 10-Q · filed 2025-07-31 | $354.30M 10-Q · filed 2025-07-31 | $524.84M derived: sum of 3 quarters · filed 2026-02-26 | $688.92M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $162.04M 10-Q · filed 2025-05-05 | $332.58M derived: sum of 2 quarters · filed 2026-02-26 | $496.66M derived: sum of 3 quarters · filed 2026-02-26 | $670.90M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $170.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $334.62M derived: sum of 2 quarters · filed 2026-02-26 | $508.86M derived: sum of 3 quarters · filed 2026-02-26 | $656.84M 10-K · filed 2026-02-26 |
| 2023-09-30 | $164.08M 10-Q · filed 2024-11-04 | $338.32M derived: sum of 2 quarters · filed 2024-11-04 | $486.29M 10-Q · filed 2024-11-04 | $634.23M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $174.24M 10-Q · filed 2024-07-29 | $322.22M 10-Q · filed 2024-07-29 | $470.15M derived: sum of 3 quarters · filed 2025-02-25 | $618.60M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $147.97M 10-Q · filed 2024-05-06 | $295.91M derived: sum of 2 quarters · filed 2025-02-25 | $444.36M derived: sum of 3 quarters · filed 2025-02-25 | $592.76M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $147.94M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $296.38M derived: sum of 2 quarters · filed 2025-02-25 | $444.79M derived: sum of 3 quarters · filed 2025-02-25 | $587.36M 10-K · filed 2025-02-25 |
| 2022-09-30 | $148.44M 10-Q · filed 2023-10-25 | $296.85M derived: sum of 2 quarters · filed 2023-10-25 | $439.42M 10-Q · filed 2023-10-25 | $595.67M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $148.40M 10-Q · filed 2023-07-27 | $290.97M 10-Q · filed 2023-07-27 | $447.22M derived: sum of 3 quarters · filed 2024-02-28 | $591.69M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $142.57M 10-Q · filed 2023-04-26 | $298.82M derived: sum of 2 quarters · filed 2024-02-28 | $443.29M derived: sum of 3 quarters · filed 2024-02-28 | $594.55M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $156.25M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $300.72M derived: sum of 2 quarters · filed 2024-02-28 | $451.99M derived: sum of 3 quarters · filed 2024-02-28 | $597.81M 10-K · filed 2024-02-28 |
| 2021-09-30 | $144.47M 10-Q · filed 2022-10-26 | $295.74M derived: sum of 2 quarters · filed 2022-10-26 | $441.56M 10-Q · filed 2022-10-26 | $588.63M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $151.27M 10-Q · filed 2022-07-27 | $297.09M 10-Q · filed 2022-07-27 | $444.16M derived: sum of 3 quarters · filed 2023-02-22 | $578.97M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | $145.82M 10-Q · filed 2022-04-27 | $292.89M derived: sum of 2 quarters · filed 2023-02-22 | $427.70M derived: sum of 3 quarters · filed 2023-02-22 | $533.18M derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-31 | $147.07M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $281.88M derived: sum of 2 quarters · filed 2023-02-22 | $387.36M derived: sum of 3 quarters · filed 2023-02-22 | $520.83M 10-K · filed 2023-02-22 |
| 2020-09-30 | $134.81M 10-Q · filed 2021-11-02 | $240.29M derived: sum of 2 quarters · filed 2021-11-02 | $373.76M 10-Q · filed 2021-11-02 | $523.23M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $105.48M 10-Q · filed 2021-07-29 | $238.95M 10-Q · filed 2021-07-29 | $388.42M derived: sum of 3 quarters · filed 2022-02-24 | $531.05M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $133.48M 10-Q · filed 2021-04-29 | $282.94M derived: sum of 2 quarters · filed 2022-02-24 | $425.57M derived: sum of 3 quarters · filed 2022-02-24 | $569.25M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $149.46M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $292.10M derived: sum of 2 quarters · filed 2022-02-24 | $435.77M derived: sum of 3 quarters · filed 2022-02-24 | $564.68M 10-K · filed 2022-02-24 |
| 2019-09-30 | $142.64M 10-Q · filed 2020-10-29 | $286.31M derived: sum of 2 quarters · filed 2020-10-29 | $415.22M 10-Q · filed 2020-10-29 | $561.68M derived: sum of 4 quarters · filed 2021-02-23 |
| 2019-06-30 | $143.67M 10-Q · filed 2020-08-10 | $272.58M 10-Q · filed 2020-08-10 | $419.05M derived: sum of 3 quarters · filed 2021-02-23 | $562.29M derived: sum of 4 quarters · filed 2021-02-23 |
| 2019-03-31 | $128.91M 10-Q · filed 2020-05-07 | $275.38M derived: sum of 2 quarters · filed 2021-02-23 | $418.62M derived: sum of 3 quarters · filed 2021-02-23 | $556.19M derived: sum of 4 quarters · filed 2021-02-23 |
| 2018-12-31 | $146.46M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23 | $289.71M derived: sum of 2 quarters · filed 2021-02-23 | $427.27M derived: sum of 3 quarters · filed 2021-02-23 | $571.50M 10-K · filed 2021-02-23 |
| 2018-09-30 | $143.25M 10-Q · filed 2019-10-25 | $280.81M derived: sum of 2 quarters · filed 2019-10-25 | $425.03M 10-Q · filed 2019-10-25 | $573.20M derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-06-30 | $137.56M 10-Q · filed 2019-07-25 | $281.79M 10-Q · filed 2019-07-25 | $429.96M derived: sum of 3 quarters · filed 2020-02-21 | $531.72M derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-03-31 | $144.22M 10-Q · filed 2019-04-29 | $292.39M derived: sum of 2 quarters · filed 2020-02-21 | $394.15M derived: sum of 3 quarters · filed 2020-02-21 | $493.15M derived: sum of 4 quarters · filed 2020-02-21 |
| 2017-12-31 | $148.17M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $249.93M derived: sum of 2 quarters · filed 2020-02-21 | $348.93M derived: sum of 3 quarters · filed 2020-02-21 | $435.51M 10-K · filed 2020-02-21 |
| 2017-09-30 | $101.76M 10-Q · filed 2018-11-01 | $200.75M derived: sum of 2 quarters · filed 2018-11-01 | $287.34M 10-Q · filed 2018-11-01 | |
| 2017-06-30 | $99.00M 10-Q · filed 2018-07-26 | $185.58M 10-Q · filed 2018-07-26 | ||
| 2016-12-31 | $349.09M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |